Robin Kirwan
Overview
Explore the profile of Robin Kirwan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
18
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apgar J, Wilkening R, Parker Jr D, Meng D, Wildonger K, Sperbeck D, et al.
Bioorg Med Chem Lett
. 2020 Nov;
32:127661.
PMID: 33160023
We previously reported medicinal chemistry efforts that identified MK-5204, an orally efficacious β-1,3-glucan synthesis inhibitor derived from the natural product enfumafungin. Further extensive optimization of the C2 triazole substituent identified...
2.
Apgar J, Wilkening R, Parker Jr D, Meng D, Wildonger K, Sperbeck D, et al.
Bioorg Med Chem Lett
. 2020 Aug;
30(17):127357.
PMID: 32738971
Our previously reported efforts to produce an orally active β-1,3-glucan synthesis inhibitor through the semi-synthetic modification of enfumafungin focused on replacing the C2 acetoxy moiety with an aminotetrazole and the...
3.
Apgar J, Wilkening R, Greenlee M, Balkovec J, Flattery A, Abruzzo G, et al.
Bioorg Med Chem Lett
. 2015 Nov;
25(24):5813-8.
PMID: 26542966
The clinical success of the echinocandins, which can only be administered parentally, has validated β-1,3-glucan synthase (GS) as an antifungal target. Semi-synthetic modification of enfumafungin, a triterpene glycoside natural product,...